RxDoctor Payments Data

Jeannie Su, MD

Urology · Santa Monica, CANPI 1922487800

Payments from drug & device makers

$11,309in general payments, 2019–2025

Across 246 payments — averaging $45.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coloplast$2K
  • Intuitive Surgical$2K
  • AbbVie$750
  • Boston Scientific$718
  • Myriad Genetic Laboratories, Inc.$688
  • Johnson & Johnson$385
  • plus $5K from 45 others

What the payments were for

  • Travel & lodging$2,28220%
  • Food & beverage$7,34765%
  • Education$1,68015%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,309 in reported general payments places this provider in the 75th percentile of 1,324 urology providers in California.

See all urology providers in California

Medicare billing

Part B allowed, 2024
$344,757
Medicare patients
313
Services billed
8,609

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide12$169,778
GemtesaVibegron98$59,754
Methenamine Hippurate71$4,812
Estradiol69$4,176
Tamsulosin Hcl126$1,986
Testosterone11$975
Finasteride79$876
Desmopressin Acetate30$802
Oxybutynin Chloride ErOxybutynin Chloride24$670
Testosterone Cypionate15$552
NitrofurantoinNitrofurantoin Macrocrystal12$238
Levofloxacin18$238
Cephalexin32$229
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst21$228
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav11$165

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi$196$169,77812 claims
Sumitomo Pharma America, Inc.Gemtesa$42$59,75498 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,324 urology providers in California.

Other urology in Santa Monica

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →